Brittany K Wise-Oringer1, Anne Claire Burghard1, Patrick O'Day2, Abeer Hassoun1, Aviva B Sopher1, Ilene Fennoy1, Kristen M Williams1, Patricia M Vuguin1, Renu Nandakumar3, Donald J McMahon4, Richard J Auchus2,5, Sharon E Oberfield6. 1. Division of Pediatric Endocrinology, Diabetes and Metabolism, Columbia University Irving Medical Center, New York, New York, USA. 2. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 3. Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, New York, USA. 4. Division of Endocrinology, Columbia University Irving Medical Center, New York, New York, USA. 5. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA. 6. Division of Pediatric Endocrinology, Diabetes and Metabolism, Columbia University Irving Medical Center, New York, New York, USA, seo8@cumc.columbia.edu.
Abstract
INTRODUCTION: Recent studies have shown 11-oxygenated androgens (11oAs) are the dominant androgens in premature adrenarche (PA). Our objective was to compare 11oAs and conventional androgens in a well-defined cohort of children with PA or premature pubarche (PP) and correlate these androgens with metabolic markers. METHODS: A prospective cross-sectional study was conducted at a university hospital. Fasting early morning serum steroids (including 11oAs) and metabolic biomarkers were compared and their correlations determined in children ages 3-8 years (F) or 3-9 years (M) with PA or PP (5 M and 15 F) and healthy controls (3 M and 8 F). RESULTS: There were no differences between PA, PP, and controls or between PA and PP subgroups for sex, BMI z-score, or criteria for childhood metabolic syndrome. Dehydroepiandrosterone sulfate (DHEAS) was elevated only in the PA subgroup, as defined. 11oAs were elevated versus controls in PA and PP although no differences in 11oAs were noted between PA and PP. Within the case cohort, there was high correlation of T and A4 with 11-ketotestosterone and 11β-hydroxyandrostenedione. While lipids did not differ, median insulin and HOMA-IR were higher but not statistically different in PA and PP. CONCLUSIONS: PA and PP differ only by DHEAS and not by 11oAs or insulin sensitivity, consistent with 11oAs - rather than DHEAS - mediating the phenotypic changes of pubarche. Case correlations suggest association of 11oAs with T and A4. These data are the first to report the early morning steroid profiles including 11oAs in a well-defined group of PA, PP, and healthy children.
INTRODUCTION: Recent studies have shown 11-oxygenated androgens (11oAs) are the dominant androgens in premature adrenarche (PA). Our objective was to compare 11oAs and conventional androgens in a well-defined cohort of children with PA or premature pubarche (PP) and correlate these androgens with metabolic markers. METHODS: A prospective cross-sectional study was conducted at a university hospital. Fasting early morning serum steroids (including 11oAs) and metabolic biomarkers were compared and their correlations determined in children ages 3-8 years (F) or 3-9 years (M) with PA or PP (5 M and 15 F) and healthy controls (3 M and 8 F). RESULTS: There were no differences between PA, PP, and controls or between PA and PP subgroups for sex, BMI z-score, or criteria for childhood metabolic syndrome. Dehydroepiandrosterone sulfate (DHEAS) was elevated only in the PA subgroup, as defined. 11oAs were elevated versus controls in PA and PP although no differences in 11oAs were noted between PA and PP. Within the case cohort, there was high correlation of T and A4 with 11-ketotestosterone and 11β-hydroxyandrostenedione. While lipids did not differ, median insulin and HOMA-IR were higher but not statistically different in PA and PP. CONCLUSIONS: PA and PP differ only by DHEAS and not by 11oAs or insulin sensitivity, consistent with 11oAs - rather than DHEAS - mediating the phenotypic changes of pubarche. Case correlations suggest association of 11oAs with T and A4. These data are the first to report the early morning steroid profiles including 11oAs in a well-defined group of PA, PP, and healthy children.
Authors: Michelle R Denburg; Miriam E Silfen; Alexandra M Manibo; Daisy Chin; Lenore S Levine; Michel Ferin; Donald J McMahon; Christina Go; Sharon E Oberfield Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Adina F Turcu; Aya T Nanba; Robert Chomic; Sunil K Upadhyay; Thomas J Giordano; James J Shields; Deborah P Merke; William E Rainey; Richard J Auchus Journal: Eur J Endocrinol Date: 2016-02-10 Impact factor: 6.664
Authors: Jan Idkowiak; Gareth G Lavery; Vivek Dhir; Timothy G Barrett; Paul M Stewart; Nils Krone; Wiebke Arlt Journal: Eur J Endocrinol Date: 2011-05-26 Impact factor: 6.664
Authors: Michael W O'Reilly; Punith Kempegowda; Carl Jenkinson; Angela E Taylor; Jonathan L Quanson; Karl-Heinz Storbeck; Wiebke Arlt Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958
Authors: Rita Santos-Silva; Manuel Fontoura; João T Guimarães; Henrique Barros; Ana Cristina Santos Journal: Pediatr Res Date: 2021-08-20 Impact factor: 3.953
Authors: Katherine Buchanan; Erin Greenup; Anna C E Hurst; Bhuvana Sunil; Ambika P Ashraf Journal: Front Endocrinol (Lausanne) Date: 2022-10-03 Impact factor: 6.055
Authors: Brittany K Wise-Oringer; Anne Claire Burghard; Heekuk Park; Richard J Auchus; Sharon E Oberfield; Anne-Catrin Uhlemann Journal: Pediatr Res Date: 2021-08-02 Impact factor: 3.953